相关实验视频

Updated: Jun 24, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

自组装的PD-L1下调器通过CDK5抑制来增强光动力激活瘤免疫疗法

Bai-Xue Yu¹, Yi-Bin Liu¹, Xia-Yun Chen¹

¹The Fifth Affiliated Hospital, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.

Small (Weinheim an der Bergstrasse, Germany)

|June 10, 2024

概括

这项研究开发了一种无抗体纳米药物 (CeSe),它结合了光动力学疗法和免疫检查点抑制. CeSe有效地抑制瘤并通过降低PD-L1的调节重新激活抗瘤免疫力,为转移性癌症治疗提供了一种新的策略.

科学领域:

纳米医学是一种纳米医学.
免疫治疗是一种免疫疗法.
癌症研究癌症研究

背景情况:

瘤免疫抑制和获得的抗性限制了抗瘤免疫力.
目前的疗法在克服免疫逃避和抵抗方面面临挑战.
需要新的策略来增强治疗性免疫反应.

研究的目的:

开发一种无抗体纳米药物 (CeSe),用于增强光动力疗法 (PDT) 和免疫疗法.
通过循环素依赖性激酶5 (CDK5) 抑制,研究CeSe在抑制编程死亡配体1 (PD-L1) 的机制.
评估CeSe在抑制初级瘤和重新激活全身抗瘤免疫力的有效性.

主要方法:

制造CeSe纳米药物使用自组装的e6 (Ce6) 和seliciclib (Se).
评估CeSe的稳定性,药物递送效率和用于PDT的活性氧物种 (ROS) 生成.
评估CeSe诱导免疫细胞死亡 (ICD),抑制CDK5,降低PD-L1和重新激活抗瘤免疫力的能力.

主要成果:

CeSe纳米药物表现出增强的稳定性和药物输送效率.
使用CeSe的PDT有效抑制了原发性瘤生长,并诱导了ICD,释放了瘤抗原.
CeSe抑制了CDK5,导致PD-L1下调,减少了瘤免疫逃逸,并重新激活了全身抗瘤免疫力.

结论:

无抗体的CeSe纳米药物为激活对转移性瘤的系统性免疫反应提供了一个有希望的策略.
CeSe通过克服免疫抑制和通过CDK5抑制和PD-L1下调来克服获得的耐药性来增强PDT和免疫治疗.
这种方法代表了转化纳米医学在癌症治疗中的重大进步.

关键词:

循环林依赖性激酶5 (CDK5) 是一种免疫原性细胞死亡免疫疗法免疫疗法光动力学疗法是一种光动力学疗法.编程死亡受体连接体1 (PD-L1)

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...